Vitreous Floaters
Conditions
Brief summary
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.
Interventions
DRUG0.01% atropine ophthalmic drop
0.01% atropine ophthalmic drop will be applied daily to the affected eye
Sponsors
Jeanette Du
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as
Exclusion criteria
will be screened as potential study participants.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Symptom improvement assessed by questionnaire | Up to 2 months | NEI VFQ-25 = National Eye Institute Visual Function Questionnaire |
Countries
United States
Contacts
Primary ContactJeanette Du, MD
Outcome results
None listed